IMV Unveils ‘Pivotal Milestone’

Dartmouth biotech company IMV on Tuesday revealed “breakthrough” results in the Phase 2 clinical trials of its flagship drug DPX-Survivac, which sparked a sell-off of its shares that was as puzzling as it was dramatic.
IMV, which specializes in using a person’s immune system to battle such diseases as cancer, announced an update on DPX-Survivac, saying the study of 22 patients with advanced